Black seed effects on coronary heart disease

The effects of black seed supplementation on metabolic profiles in type 2 diabetic patients with coronary heart disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N61

Enrollment

Registered

2019-07-22

Start date

2017-09-05

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease. Chronic ischemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: Four N. Sativa containing capsules (Barij Essence, Kashan, Iran), 500 mg each capsule, daily, for 24 weeks orally. Intervention 2: Control group: Placebo (Barij Ess

Eligibility

Sex/Gender

All

Age

45 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients aged 45-85 years People diagnosed with type 2 diabetes and coronary heart disease

Exclusion criteria

Exclusion criteria: Patients with thyroid disorders. Severe renal insufficiency hepatic failure Those experiencing an acute myocardial infarction within the past 3 months Patients undergoing cardiac surgery within the past 3 months

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Calculation using homeostasis model of assessment insulin resistance formula.	—

Secondary

Measure	Time frame
Total antioxidant capacity. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Fasting serum insulin levels. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL) cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Total antioxidant capacity. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Fasting serum insulin levels. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL) cholesterol. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fariba Raygan

Kashan University of Medical Sciences

raygan.fariba2@gmail.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026